JAMA Network
About The Study: The symptoms reported after administration of the Pfizer-BioNTech COVID-19 vaccine were comparable overall to those for approved non–SARS-CoV-2 vaccines in this study including 7,800 children younger than age 5. The data may be used together with prospective licensure studies of BNT162b2 efficacy and safety and could help guide expert recommendations about BNT162b2 vaccinations in this age group.
Authors: Cho-Ming Chao, M.D., Ph.D., of the University of Rostock in Rostock, Germany, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.37140)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
